Nasdaq:IRON
Disc Medicine, Inc.
A clinical-stage medical device company commercializing minimally invasive spinal instrumentation systems through its Disc-10 platform.
Key Metrics
Investment Thesis
Bull Case
Investors may view IRON as a high-potential turnaround story if their R&D investments successfully translate into approved products that generate revenue from the zero-revenue baseline. The company's massive marketable securities portfolio of $700M acts as a substantial hidden asset buffer against current operational losses, providing significant downside protection.
Bear Case
The widening net loss trend and complete absence of revenue present a critical path risk for any public investor considering the stock. With operating expenses at $236.0M and no cost of revenue or gross profit currently realized, the company is burning through capital without a clear commercialization timeline to offset the accelerating losses.
About Disc Medicine, Inc.
Disc Medicine, Inc. (IRON) is a medical device manufacturer specializing in minimally invasive spinal instrumentation systems. The company primarily serves the orthopedic surgery market with its proprietary Disc-10 technology designed to treat disc herniations and degenerative disc disease. Key products include the Disc-10 system and associated surgical instruments aimed at reducing recovery time for patients.
Analysis
Management Discussion
The company has experienced a substantial decline in profitability over the last three years, with net losses expanding from -$76.4M in 2023 to -$212.2M in 2025. Despite this widening deficit, the firm maintains a strong liquidity position with $91.4M in ending cash and significant non-operating interest income of $27.8M, though operating expenses remain high at $236.0M.
Industry Overview
The medical device industry is characterized by high barriers to entry due to stringent regulatory requirements and lengthy clinical trial processes. Companies in this sector often operate with thin margins until products achieve widespread adoption, though successful entrants can command premium pricing for innovative technologies that solve unmet patient needs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $47.5M | $91.1M | $129.7M | $236.0M |
| Operating Income | $-47.5M | $-91.1M | $-129.7M | $-236.0M |
| R&D | $33.4M | $69.3M | $96.7M | $170.6M |
| G&A | $14.0M | $21.9M | $33.0M | $65.4M |
| Stock-Based Comp | $2.1M | $5.5M | $16.8M | $34.3M |
| D&A | $89.0K | $100.0K | $156.0K | $281.0K |
| Depreciation | — | — | $200.0K | — |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $14.8M | $20.7M | $24.2M |
| Interest Income | $709.0K | $14.8M | $21.3M | $27.8M |
| Pre-Tax Income | $-47.5M | $-76.3M | $-109.0M | $-211.8M |
| Income Tax | $-648.0K | $99.0K | $355.0K | $361.0K |
| Continuing Ops | $-46.8M | $-76.4M | $-109.4M | $-212.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-46.8M | $-76.4M | $-109.4M | $-212.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-46.8M | $-76.4M | $-109.4M | $-212.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $198.5M | $365.7M | $493.6M | $803.9M |
| Cash & Equivalents | $194.6M | $360.4M | $192.4M | $91.1M |
| Marketable Securities | — | — | $297.4M | $700.0M |
| Prepaid Expenses | — | — | $3.7M | $12.7M |
| Other Current Assets | $3.9M | $5.3M | $0 | $0 |
| Long-Term Assets | $1.7M | $2.3M | $3.2M | $3.0M |
| PP&E (Net) | $168.0K | $170.0K | $751.0K | $1.2M |
| Operating Leases | $1.4M | $1.9M | $1.6M | $1.1M |
| Other LT Assets | $116.0K | $234.0K | $838.0K | $726.0K |
| Total Assets | $200.2M | $368.0M | $496.8M | $806.9M |
| Current Liabilities | $22.6M | $21.4M | $23.3M | $36.6M |
| Accounts Payable | $16.2M | $12.6M | $7.9M | $9.0M |
| Current Leases | $307.0K | $665.0K | $130.0K | $611.0K |
| Other Current Liab | $0 | $0 | $7.1M | $11.5M |
| Long-Term Liabilities | $1.0M | $1.4M | $29.9M | $30.4M |
| LT Operating Leases | $1.0M | $1.4M | $1.5M | $1.3M |
| Other LT Liab | $0 | $0 | $28.3M | $29.2M |
| Total Liabilities | $23.6M | $22.9M | $53.2M | $67.1M |
| Shareholders' Equity | $176.6M | $345.1M | $443.6M | $739.8M |
| Paid-In Capital | $288.8M | $533.8M | $741.3M | $1.25B |
| Retained Earnings | $-112.2M | $-188.6M | $-298.0M | $-510.2M |
| AOCI | — | — | $289.0K | $965.0K |
| Total L&E | $200.2M | $368.0M | $496.8M | $806.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-46.8M | $-76.4M | $-109.4M | $-212.2M |
| Non-Cash Adjustments | $3.3M | $3.6M | $20.5M | $14.7M |
| Working Capital Changes | $1.3M | $-621.0K | $-5.1M | $17.1M |
| Cash from Operations | $-42.3M | $-73.5M | $-93.9M | $-180.4M |
| Capital Expenditures | $151.0K | $89.0K | $505.0K | $933.0K |
| Cash from Investing | $-151.0K | $-89.0K | $-292.3M | $-394.3M |
| Debt Issuances | — | — | $29.0M | $0 |
| Cash from Financing | $149.0M | $239.4M | $218.3M | $473.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $106.6M | $165.8M | $-167.9M | $-101.3M |
| Beginning Cash | $88.2M | $194.8M | $360.6M | $192.7M |
| Ending Cash | $194.8M | $360.6M | $192.7M | $91.4M |
Frequently Asked Questions
How does Disc Medicine, Inc. make money?
The company's financial profile indicates a focus on research and development rather than traditional product sales, with significant investments in R&D ($170.6M) and substantial marketable securities holdings ($700M) suggesting a biotech or clinical-stage strategy dependent on regulatory approval and future commercialization milestones.
What are the main risks for IRON?
Significant net losses widening from -$46.8M in 2022 to -$212.2M in 2025 indicating unsustainable burn rates without revenue, lack of current revenue stream with reported zero cost of revenue and gross profit, dependence on successful regulatory approval for future income generation, and potential dilution risks given the large cash flow from financing inflows.
What is IRON's competitive advantage?
Proprietary Disc-10 technology offering a unique approach to spinal procedures, a robust balance sheet with $91.1M in cash providing runway for development, and strategic partnerships that may facilitate market entry once products gain regulatory clearance.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.